Vol
6. Issue 37 / December 4, 2006 |
|||||||
Etcetera
In his current project, Mosnier aims to improve our understanding of the cytoprotective properties of blood coagulation proteases. Building on recent successes with engineered variants of the blood coagulation protease activated protein C, he will use protein engineering approaches to improve the cytoprotective properties of other blood coagulation proteases. These engineered variants could potentially provide improved and novel therapeutics for thrombotic and inflammatory disorders. Benjamin Hafensteiner and William Brenzovich Receive Eli Lilly Fellowships
Send comments to: mikaono[at]scripps.edu
|
|
||||||